Internal Medicine, Hematology & Oncology · Dallas, TX
NPI
1003256553
Since 2013
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
2201 Inwood Rd # Nc2.130
Dallas, TX, 75235
Phone (214) 645-4673
Groups this clinician bills Medicare through
Medicare paid, 2024
$51K
508 services
Medicare patients, 2024
153
Average age 74
Drug cost, 2024
$6.1M
1,548 prescriptions
Company payments, 2025
$14K
From 13 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Yazan Madanat was code 99215 (office e&m - established), 189 times for 96 patients. In total Yazan Madanat billed 508 services in 8 codes, and Medicare paid $51K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2019-06-10.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99215 Office E&M - Established | Facility | 189 | 96 | $110.08 | $21K |
| 99233 Hospital E&M - Subsequent | Facility | 127 | 24 | $90.15 | $11K |
| 99215 Office E&M - Established | Office | 76 | 57 | $117.19 | $8,907 |
| 99214 Office E&M - Established | Office | 53 | 36 | $75.38 | $3,995 |
| 99214 Office E&M - Established | Facility | 30 | 24 | $75.68 | $2,270 |
By year: 2022 $96K for 995 services; 2023 $67K for 723 services; 2024 $51K for 508 services.
Medicare prescription drug claims, 2024
In 2024, the drug Yazan Madanat prescribed most often to Medicare patients was Acyclovir, with 270 prescriptions and refills. In total Yazan Madanat wrote 1,548 Medicare prescriptions that cost $6.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Acyclovir Generic | 270 | 442 | 73 | $3,331 |
| Allopurinol Generic | 131 | 246 | 36 | $923 |
| Jakafi Ruxolitinib Phosphate | 88 | 90 | 13 | $1.5M |
| Levofloxacin Generic | 83 | 87 | 33 | $1,301 |
| Ursodiol Generic | 65 | 89 | 18 | $5,986 |
| Pantoprazole Sodium Generic | 63 | 124 | 20 | $857 |
| Ondansetron Hcl Generic | 42 | 42 | 23 | $245 |
| Idhifa Enasidenib Mesylate | 37 | 37 | Under 11 | $1.2M |
| Potassium Chloride Generic | 36 | 58 | 16 | $1,110 |
| Besremi Ropeginterferon Alfa-2b-Njft | 30 | 30 | Under 11 | $469K |
| Prochlorperazine Maleate Generic | 29 | 29 | 23 | $275 |
| Cefpodoxime Proxetil Generic | 26 | 30 | Under 11 | $3,050 |
| Valacyclovir Valacyclovir Hcl | 25 | 37 | Under 11 | $1,378 |
| Inqovi Decitabine/Cedazuridine | 25 | 26 | Under 11 | $194K |
| Levocetirizine Dihydrochloride Generic | 25 | 33 | Under 11 | $1,091 |
Brand drugs: - claims; generic drugs: 1,167 claims; opioid claims: 13.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Yazan Madanat $14K ($14K in general payments such as food, travel and fees) from 13 companies. The largest payer was Takeda Pharmaceuticals U.S.A., Inc. with $3,329.
| Company | Payments | Amount |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 2 | $3,329 |
| Geron Corporation GERN | 5 | $2,866 |
| Blueprint Medicines Corporation SNY | 2 | $2,709 |
| Syndax Pharmaceuticals, Inc. SNDX | 3 | $2,550 |
| Abbvie Inc. ABBV | 1 | $2,175 |
| Novartis Pharmaceuticals Corporation NVS | 1 | $725 |
| Janssen Scientific Affairs, LLC JNJ | 1 | $54.81 |
| Sobi, Inc SOBI.ST | 1 | $14.99 |
| Tempus AI, Inc TEM | 1 | $14.4 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.